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Abstract
Kaposi’s sarcoma herpesvirus (KSHV) encodes a cluster of twelve micro (mi)RNAs, which are abundantly expressed during
both latent and lytic infection. Previous studies reported that KSHV is able to inhibit apoptosis during latent infection; we
thus tested the involvement of viral miRNAs in this process. We found that both HEK293 epithelial cells and DG75 cells
stably expressing KSHV miRNAs were protected from apoptosis. Potential cellular targets that were significantly down-
regulated upon KSHV miRNAs expression were identified by microarray profiling. Among them, we validated by luciferase
reporter assays, quantitative PCR and western blotting caspase 3 (Casp3), a critical factor for the control of apoptosis. Using
site-directed mutagenesis, we found that three KSHV miRNAs, miR-K12-1, 3 and 4-3p, were responsible for the targeting of
Casp3. Specific inhibition of these miRNAs in KSHV-infected cells resulted in increased expression levels of endogenous
Casp3 and enhanced apoptosis. Altogether, our results suggest that KSHV miRNAs directly participate in the previously
reported inhibition of apoptosis by the virus, and are thus likely to play a role in KSHV-induced oncogenesis.
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Introduction
The development of cancer is linked to six major hallmarks that
explain how cells transgress from a normal to a neoplastic state,
including (i) sustained proliferative signaling, (ii) evasion of growth
suppression, (iii) activated invasion and metastasis, (iv) enabled
replicative immortality, (v) induced angiogenesis and (vi) resistance
to cell death [1]. There is ample evidence that programmed cell
death or apoptosis functions as a barrier to cancer development
(reviewed in [2]). Many different factors, including environmental
ones, contribute to the origin and progression of cancer. For
example, infection by microbial pathogens sometimes leads to
tumor development. Several viruses have been recognized as
causal agents of specific types of cancer, and up to 20% of all
human cancers are associated with single or multiple viral
infections. One such oncogenic virus is Kaposi’s sarcoma-
associated herpesvirus (KSHV), the primary etiological agent of
Kaposi’s sarcoma, which is a highly angiogenic tumor most
probably arising from the endothelium and developing primarily
in immunocompromised individuals. KSHV-infection is also
associated with aggressive lymphomas such as primary effusion
lymphoma and multicentric Castleman’s disease [3]. Like many
viruses, KSHV has been shown to inhibit apoptosis, and possesses
a truly impressive arsenal to do so (reviewed in [4,5]).
Viruses have acquired an extraordinary capacity to evolve and
adapt to their host, which translates into an incessant battle
between the infected organism and the virus. One of the latest
discoveries reflecting this continuous arms race is that certain
mammalian viruses encode for miRNAs. In mammals, miRNAs
constitute one of the most important classes of regulatory RNAs
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[6,7]. Their biogenesis involves the processing of a large primary
transcript into a stem-loop pre-miRNA, ultimately leading to the
mature single stranded ,22 nt miRNA (reviewed in [7–11]). This
functional miRNA is incorporated into an RNA-induced silencing
complex (RISC) that invariably contains a member of the
Argonaute protein family. Once loaded, the active RISC can be
directed towards its messenger RNA target to regulate, predom-
inantly negatively, its translation (see references [12,13] for
review). The fact that target RNAs are frequently destabilized
justifies the use of large-scale approaches to look at global changes
in transcriptomic profiles as a way to identify miRNA targets [14].
To date, the vast majority of reported miRNA/mRNA interac-
tions involve binding of the miRNA to the 39 untranslated region
(UTR) of the transcript through an imperfect base-pairing
mechanism in which nucleotides 2 to 8 of the miRNA (the seed)
appear to play an important role [15]. However, other types of
interactions, such as binding in the coding sequence or in the 59
UTR, or with bulges in the seed region, have also been reported
[16–18].
The use of small non-coding RNAs such as miRNAs to regulate
gene expression makes perfect sense for viruses, allowing them to
modulate the cellular environment in a non-immunogenic manner
[19]. The first virus-encoded miRNAs were identified in Epstein-
Barr virus [20], and subsequent studies concluded that many
herpesviruses, including Kaposi’s sarcoma herpesvirus (KSHV)
encode miRNAs (reviewed in [21]). KSHV has been shown to
encode 12 miRNAs [22–25], which are clustered in the vicinity of
the major KSHV latency transcript, K12. KSHV-miR-K12-1 to
miR-K12-9, and miR-K12-11 are located in the intron of the
larger kaposin transcript, while miR-K12-10 maps to the coding
region, and miR-K12-12 resides within the 39 UTR of the K12
coding sequence. Some cellular targets of KSHV miRNAs have
been identified, mostly for miR-K12-11, which shares an identical
seed sequence with the cellular miRNA miR-155 [26,27].
Here, we show that KSHV miRNAs also contribute to the
inhibition of apoptosis in infected cells. We show that cell lines
expressing KSHV miRNAs are less sensitive to both caspase-
dependent and -independent apoptosis induction by staurosporine
or etoposide. Using a microarray approach, we identified caspase
3 (Casp3) as a target of some of these viral miRNAs. Casp3 is a
well-known effector caspase (reviewed in [28]) that is critical for
apoptosis induction. Using site-directed mutagenesis, we found
that KSHV miR-K12-1, K12-3 and K12-4-3p are responsible for
Casp3 regulation. Finally, by blocking the function of these
miRNAs in infected cells, we showed that both Casp3 levels and
apoptosis were increased.
Results
Cell lines expressing KSHV miRNAs are less sensitive to
apoptosis
We generated inducible HEK293 cells (FLP-293) expressing the
intronic KSHV miRNAs under a doxycycline-inducible CMV
promoter. To this end, the sequence spanning the ten intronic
miRNAs miR-K12-1 to 9 and miR-K12-11 (K10/12) (Figure 1A)
was inserted into the pcDNA5/FRT/TO plasmid, and used to
transfect Flp-In T-Rex-293 cells. Stable cell lines were obtained by
hygromycin selection, and subsequently named FLP-K10/12. As a
negative control, we generated stable cells transfected with a
pcDNA5 plasmid with no insert, that we then named FLP-
pcDNA. We verified by northern blot analysis that doxycycline
treatment readily induced the expression of the miRNAs to level
similar to that found in the KSHV-infected BCBL-1 cells [29]
(Figure 1B). In all following experiments, we used a final
concentration of doxycycline of 1 mg/mL. We also measured by
northern blot analysis the level of KSHV miRNAs expression in
the induced FLP-K10/12 cells and compared it to KSHV-infected
BCBL-1 and BC3 cells [30]. We found that expression of the
miRNAs was slightly higher than in BCBL-1, but lower than in
BC-3 cells (Figure S1), suggesting expression close to physiological
levels. To assess the effect of KSHV miRNA expression on
apoptosis, we first grew the FLP-pcDNA and -K10/12 cell lines in
the presence of doxycycline to induce expression of the viral
miRNAs, and then treated them for 8 h with 2 mM of
staurosporine, a well-described inducer of apoptosis [31], or
DMSO as a control. To measure the effect of this treatment on
apoptosis we used Annexin V binding assay, which allows
quantification of the level of phosphatidylserine exposure at the
outer membrane side, a well characterized event of early apoptosis
[32]. In addition, cells were labeled with propidium iodide (PI),
staining both apoptotic and necrotic cells. Statistical analysis of six
independent cell-sorting experiments revealed that Annexin V
binding levels following staurosporine treatment were not
significantly different in the presence or absence of doxycycline
for the control FLP cell line (Figure 1C). In contrast, concerning
the FLP-K10/12 cell line, a statistically significant decrease in
Annexin V levels after staurosporine treatment was observed
following doxycycline-induced expression of the microRNAs
(Figure 1C). Figure 1D shows one representative experiment of
the six biological replicates. In order to get an independent
measure of apoptosis, we monitored the activity of effector
caspases using a DEVD-aminoluciferin substrate for Casp3 and
Casp7 that is measurable by a luciferase assay. As shown in
Figure 1E, the luminescent Casp3/7 activity induced by 2 or 5 mM
of staurosporine treatment of the stable FLP-K10/12 cells was
sharply decreased (2.5 to 3 times) upon doxycycline induction of
the KSHV miRNAs expression, while it remained unchanged in
the control FLP-pcDNA cells.
To monitor the effect of KSHV miRNAs on apoptosis in a cell
line more physiologically relevant for KSHV infection, we used
the previously described DG-75-K10/12 cells -a Burkitt lympho-
ma cell line [33,34] lentivirally transduced with a construct
expressing KSHV intronic miRNAs [35]-, and measured the effect
of KSHV miRNAs expression on apoptosis in either the DG-75-
K10/12 cells or the DG-75-EGFP control cells. Statistical analysis
of four independent experiments confirmed that staurosporine
treatment readily induced phosphatidylserine exposure in the
Author Summary
MiRNAs are small, non-coding RNAs that regulate gene
expression post-transcriptionally via binding to comple-
mentary sites in target mRNAs. This evolutionary con-
served regulatory system is present in most eukaryotes,
and it has recently been shown that certain viruses have
evolved to express their own miRNAs. Due to their non-
immunogenic nature, viral miRNAs represent an efficient
tool for the virus to control its environment. Here we show
that KSHV miRNAs are involved in the control of apoptosis
both when expressed in stable cell lines and in the context
of viral infection. Using a microarray based approach we
identified putative cellular targets, among which the
effector caspase 3 is targeted by three of the viral miRNAs.
Finally, we showed that blocking these miRNAs in infected
cells resulted both in increased Casp3 levels and a higher
apoptosis rate. These findings indicate that miRNAs of viral
origin are key players in cell death inhibition by KSHV.
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control cell line, but that this induction was significantly reduced in
the K10/12-expressing cells (Figure 2A). A representative
experiment of the biological replicates (Figure 2B) shows that the
percentage of Annexin V positive cells dropped almost two-fold in
DG-75-K10/12 cells vs. DG-75-EGFP cells after 8 h of staur-
osporine treatment. As opposed to the FLP-293 cells, we were
unable to induce Casp3/7 activity with staurosporine in the DG75
cells (data not shown). In line with this observation, it has been
reported previously that in this particular cell line, the apoptotic
protease-activating factor 1 (APAF-1) was sequestered at the
plasma membrane, which prevents caspase activation [36].
Microarray analysis of KSHV miRNAs-expressing cell lines
In order to identify putative cellular targets of KSHV miRNAs
involved in the miRNA-induced anti-apoptotic phenotype, we
used a microarray approach on the two main cell types that are
infected in vivo by KSHV: endothelial cells and B lymphocytes. In
addition to the already described DG-75-K10/12 and DG-75-
EGFP cells, we also generated by lentiviral transduction
endothelial cells EA.hy926 [37] expressing the K10/12 construct
or EGFP as a control. In order to determine the relative expression
of KSHV miRNAs were expressed in the DG-75-K10/12 cells, we
cloned the small RNA population of these cells and analyzed it by
Solexa deep-sequencing. As can be seen in Table S1, KSHV
miRNAs represented more than 18% of the total miRNAs in this
cell line, which is slightly less than what has been previously
described for BCBL1 cells ([38] and data not shown). All intronic
miRNAs accumulated to measurable levels with the exception of
miR-K12-11, which seemed to be expressed at a low level. We
then measured by qRT-PCR the levels of some KSHV miRNAs
expression in EA.hy926 and DG-75-K10/12 cells compared to
BCBL-1 cells (Table S2). The levels of viral miRNAs expression in
both cell lines correlated very well (r = 0,93) (Figure S2).
DG-75 and EA.hy926 EGFP control- and miRNA- expressing
cell lines were analyzed in triplicate on Affymetrix Human
Genome U133 Plus 2.0 microarrays. The clustering of the gene
expression profiles primarily correlated with the cell line (DG-75
vs. EA.hy926), but also within each cell line with the expression of
KSHV miRNAs (Figure S3). In addition, the changes in gene
expression levels following the KSHV miRNAs transduction
correlated weakly (r = 0.19) but significantly (p,10215 at Pearson’s
test) between the two cell lines (Figure S4).
Target recognition by miRNAs involves a number of determi-
nants, the most important of which appears to be perfect base-
pairing of nucleotides 2–7 of the miRNA (the seed), together with
either an adenosine opposite miRNA nucleotide 1, or an
additional base pair involving the 8th nucleotide of the miRNA
[15]. In single miRNA transfection experiments one typically
observes that the mRNAs that carry matches to the transfected
miRNA are significantly down-regulated in response to transfec-
tion compared to mRNAs that do not carry such matches. To
determine whether the KSHV miRNAs significantly influenced
gene expression levels in a complex experiment such as ours, in
which multiple miRNAs are simultaneously induced, we designed
the following test. We first computed a KSHV miRNA sensitivity
score for each mRNA, defined as the sum over all KSHV
miRNAs, the number of matches of the 39 UTR to the seed of the
KSHV miRNA multiplied by the relative abundance of the
KSHV miRNA. The relative abundances of the KSHV miRNAs
were determined using the DG-75-K10/12 small RNAs deep-
sequencing data. The KSHV miRNA sensitivity scores are
reported in Dataset S1. We then compared the change in
expression level of the 1000 mRNAs with highest KSHV miRNA
sensitivity score and of mRNAs with no seed matches to the
KSHV miRNAs in the 39 UTR and found that the KSHV
miRNA sensitive mRNAs were significantly down-regulated in
both KSHV miRNA expressing DG-75 and EA.hy926 cells
(p,1023 and p,10215, respectively in Wilcoxon’s rank sum test).
We observed however, that the 39 UTRs of the 1000 mRNAs with
highest KSHV sensitivity were on average ten times longer than
the 39 UTRs with no seed matches (Figure S5). To test whether
differences in 39 UTR length alone could account for the down-
regulation of the KSHV sensitive mRNAs, we computed the
average fold change of 1000 mRNAs sampled in such way that
their 39 UTR length distribution was the same as that of the
KSHV sensitive mRNAs (Figure 3A, blue bars). We repeated this
procedure 1000 times and found that the set of 1000 KSHV
sensitive mRNAs still exhibited a stronger down-regulation
compared to mRNAs of similar 39 UTR length (Figure 3A, red
bars) (p = 0.036 and 0.002, respectively for the expression changes
computed from the DG-75 and EA.hy926 samples). Therefore, the
39 UTR length alone cannot explain the magnitude of down-
regulation of the most KSHV sensitive mRNAs in response to
KSHV miRNA expression. These results indicated that KSHV
miRNAs exert a detectable effect on mRNA expression in these
cell lines and motivated us to proceed with further characterization
of candidate direct targets.
As KSHV putative direct targets we extracted transcripts that
were significantly down-regulated significantly in the replicate
experiments, and which contained at least one seed-match to one
of the KSHV miRNAs. We identified 704 putative direct targets in
DG-75 cells (Figure 3B), and 980 putative direct targets in
EA.hy926 cells (Figure 3C). A complete list of putative direct
targets can be found in Dataset S2 for DG-75 cells and in Dataset
S3 for EA.hy926 cells. The overlap between the two datasets
contained 153 putative direct targets (Dataset S4).
Validation of putative KSHV miRNA targets
In order to validate direct cellular targets of KSHV miRNAs,
we turned to classical reporter assays in HEK293 cells (293A
cells). We chose, among genes involved in pathways such as cell
cycle regulation, DNA damage repair, and apoptosis, a subset of
the 39 UTR sequences identified as putative direct targets by our
previous analysis. These candidates were then cloned 39 to the
firefly luciferase gene in the dual-reporter vector psiCHECK-2,
also encoding a Renilla luciferase as a standard. We cloned and
Figure 1. HEK293 cells expressing KSHV miRNAs are less sensitive to apoptosis. A. Schematic representation of KSHV miRNA genomic
localization, and of the K10/12 construct that was used for their expression. B. Northern blot analysis of inducible FLP-K10/12 cells. Cells were grown
for 48h with increasing concentration of doxycycline (0 to 1 mg/mL); a concentration of 1 mg/mL was used in the following experiments. KSHV latently
infected BCBL-1 cells were used as a positive control. C. Statistical analysis of apoptosis induction measured by Annexin V binding assay in FLP-
pcDNA control cell line (left panel) or FLP-K10/12 (right panel) grown continuously in doxycycline-containing medium, and treated with DMSO or
staurosporine for 8 h. Error bars represent the standard deviation observed for 6 biological replicates; a significant difference (p = 0.0306) of apoptosis
induction is observed between the non-treated and doxycycline-treated K10/12 expressing cell lines, but not for the pcDNA cell line. D. Dot plot
examples of a representative FACS analysis of annexin V and propidium iodide (PI) levels in FLP-pcDNA (left panel) or FLP-K10/12 cells (right panel). E.
The same cells treated for 8 h with DMSO or 2 and 5 mM staurosporine, were assayed for Casp3/7 activity after addition of a luminescent substrate for
the caspases, and normalized to the total protein content. The ratio between doxycycline-treated and non-treated cells is given.
doi:10.1371/journal.ppat.1002405.g001
Apoptosis Regulation by KSHV microRNAs
PLoS Pathogens | www.plospathogens.org 4 December 2011 | Volume 7 | Issue 12 | e1002405
tested the full length 39 UTR of sixteen candidate targets, which
were tested in multiple independent assays. We first assessed that
the K10/12 construct could repress the activity of luciferase
sensors containing bulged complementary sequence (with a bulge
at positions 9 to 12) to some of the KSHV miRNAs. For all of the
KSHV miRNAs tested, except miR-K12-9, we could show a
strong repression in the presence of pcDNA-K10/12 (Figure 4A).
The lack of miR-K12-9 activity could relate to its lower
expression in the context of the K10/12 construct (Tables S1
and S2). As opposed to what would have been expected based on
the DG-75-K10/12 small RNA sequencing data, miR-K12-11
appeared to be functional in the FLP-K10/12, and we confirmed
that it accumulated in higher amounts in these cells compared to
the DG-75-K10/12 cells (data not shown). As a positive control
Figure 2. DG-75 cells expressing KSHV miRNAs are less sensitive to apoptosis. A. Statistical analysis of apoptosis induction measured by
Annexin V binding assay in stable DG-75-EGFP cells as a control or DG-75-K10/12, treated for 8 h with DMSO or staurosporine. Error bars represent
the standard deviation observed for 4 biological replicates; a significant difference of apoptosis induction (p = 0.0355) is observed between the EGFP
and the K10/12 expressing cell lines. B. Dot plot examples of a representative FACS analysis of annexin V and propidium iodide (PI) levels in EGFP
(upper panels), or K10/12 DG-75 cells (lower panels).
doi:10.1371/journal.ppat.1002405.g002
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for the luciferase assays with the selected putative targets, we used
SPP1, a previously validated target of KSHV miRNAs [39]. The
validation assays showed that only a subset of the 39 UTRs tested
resulted in a measurable repression of luciferase activity
(Figure 4B). Among all the tested candidates, we observed the
most important and reproducible down-regulation for two genes,
Rad51AP1, involved in DNA damage repair, and Casp3, one of
the main effectors involved in apoptosis induction. The
RAD51AP1 reporter showed a down-regulation of 30 to 40%
across luciferase experiments, while the Casp3 reporter showed a
down-regulation of 40 to 50% (Figure 4B). We thus hypothesized
that the anti-apoptotic phenotype of KSHV miRNA-expressing
cells could be in part caused by the regulation of Casp3, and
decided to continue this study by focusing on this protein.
Targeting of Casp3 by miR-K12-1, K12-3 and K12-4-3p
The initial analysis of Casp3 39 UTR revealed 8mer or 7mer
seed-matches [15] for miR-K12-4-3p (one M8A1 site), miR-K12-1
(two M8 sites), and miR-K12-3 (one A1 site). In addition, 6mer
seed-matches to miR-K12-1, miR-K12-2 and miR-K12-10a could
Figure 3. Microarray analysis of KSHV miRNAs expressing cell lines. A. Changes in expression levels of KSHV miRNA sensitive mRNAs,
mRNAs without KSHV miRNA seed matches in their 39 UTR, and randomized sets of genes with the same 39 UTR length distribution as KSHV miRNA
sensitive mRNAs. The analysis was performed separately in DG-75 and EA.hy926 cells. Error bars represent 95% confidence interval on the mean fold
change in gene expression upon transducing the KSHV miRNAs. Dot plot representation of the changes in gene expression observed in the DG-75
cells (B), and in the Ea.hy926 cells (C). The potential targets (black crosses) tested by luciferase assay were selected among the genes down-regulated
1.4 to 4 fold (indicated by the green lines).
doi:10.1371/journal.ppat.1002405.g003
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Figure 4. Validation of putative targets of KSHV miRNAs by luciferase assays. Luciferase assays were performed in triplicate 48 h post-
transfection. The experiments were repeated at least 3 times, and one representative experiment is shown. A. KSHV miRNAs expressed from the
pcDNA-K10/12 plasmid, but not miR-K12-9, can regulate the expression of sensor constructs containing complementary sequence to individual KSHV
miRNAs. All differences but for miR-K12-9 were statistically significant (p,0.01). B. Dual-luciferase assay with psiCHECK-2 constructs containing either
no UTR, or the indicated 39 UTR. 293A cells were co-transfected with the luciferase construct and an empty pcDNA, or pcDNA-K10/12 construct.
(* p,0.01).
doi:10.1371/journal.ppat.1002405.g004
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be found (Figure 5A). In order to further identify regions of the
Casp3 39 UTR that were susceptible to regulation by KSHV
miRNAs, we subdivided the 39 UTR in three parts and cloned
them in the reporter vector. None of the tested fragments showed
such a strong repression as the full-length sequence, suggesting
that all putative miRNA binding sites are required for efficient
repression, or that the binding sites function optimally only in their
natural context (Figure S6). We then transfected pcDNA
constructs expressing individual miRNAs (miR-K12-1 to -6,
K12-9 and K12-10) to identify whether a single, or multiple
miRNAs, mediated Casp3 regulation. We found that as suggested
by the seed-matches quality, miR-K12-1, K12-3 and K12-4-3p (in
decreasing order of repression observed) were able to significantly
regulate the expression of the reporter fused to the 39 UTR of
Casp3 (Figure 5B). Expression of miR-K12-2 and K12-10, or of
miRNAs with no predicted seed-matches (miR-K12-5, K12-6 and
K12-9) had no effect on the Casp3 sensor.
Subsequently, we aimed at determining which of the five
putative binding sites for miR-K12-1, K12-3 and K12-4-3p were
most important for Casp3 downregulation. To this end, we
mutagenized each individual seed-match by introducing three
point mutations to disrupt miRNA binding in the luciferase sensor
containing Casp3 39 UTR (Figure 6A). The resulting luciferase
reporters were tested with miRNA expression constructs for either
the 10 intronic miRNAs, or the individual miR-K12-1, K12-3 and
K12-4-3p. As shown in Figure 6B, only the 39 proximal binding
site for miR-K12-1 appears to be functional, as the Casp3 Mut
K12-1 39 luciferase sensor could not be regulated by the pcDNA-
K10/12 or the pcDNA-K12-1 constructs. The binding site for
miR-K12-3 was also validated, as the mutant luciferase sensor for
this miRNA is not regulated by the pcDNA-K10/12 or the
pcDNA-K12-3 construct (Figure 6C). Finally, the binding site for
miR-K12-4-3p was validated, although it seems to be less potent
than the two others in terms of luciferase regulation (Figure 6D). In
conclusion, we showed that Casp3 39 UTR is regulated via three
binding sites for (from 59 to 39) miR-K12-4-3p, K12-3 and K12-1.
The positions of these sites explain why the luciferase assay done
with the Casp3 39 UTR fragments (Figure S6) did not reveal
obvious differences as each individual fragment contained one of
the three validated sites.
Figure 5. Caspase 3 is targeted by several KSHV miRNAs. Luciferase assays were performed multiple times in triplicate 48 h post-transfection.
A. Schematic representation of Casp3 39 UTR showing potential seed-matches for KSHV miRNAs. The seed-match types are described in the text. B.
Dual luciferase assays performed in 293A cells with the Casp3 luciferase sensor and pcDNA constructs expressing the indicated individual miRNAs.
Luciferase ratios relative to empty psiCHECK-2 set to 1 are displayed. (* p,0.01).
doi:10.1371/journal.ppat.1002405.g005
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KSHV miRNAs decrease endogenous Casp3 levels
In order to measure the effect of KSHV miRNAs on
endogenous Casp3, we first performed real-time quantitative
PCR analysis of 293A cells following primary infection and
antibiotic selection of rKSHV infected cells [40]. We found that
the level of Casp3 transcript decreased two fold following
infection (Figure 7A, left panel). We also measured the level of
Casp3 mRNA in the doxycycline-inducible FLP cells, and
observed a similar down-regulation upon induction in FLP-
K10/12 cells, but not in control FLP-pcDNA cells (Figure 7A,
right panel). We then measured Casp3 protein levels in FLP-
K10/12 and DG-75-K10/12 cells, and observed a significant
down-regulation in three independent experiments (average of
0.63-fold, p = 0.0005 and 0.69-fold, p = 0.0046 respectively)
(Figure 7B and C). We then turned to HUVEC endothelial cells,
one of the two main cellular types infected in vivo by KSHV, and
Figure 6. Identification of KSHV miRNAs binding sites in the 39 UTR of Casp3 transcript by mutational analysis. Luciferase assays were
performed multiple times in triplicate, 48 h post-transfection. A. Schematic representation of Casp3 luciferase sensor and of the mutagenesis
performed within the potential binding sites of miR-K12-1, miR-K12-3 and miR-K12-4-3p. A mutant was generated for each potential miRNA binding
site. Dual luciferase assays were performed with the Casp3 luciferase wild type (WT) or mutant sensors and pcDNA constructs expressing either the
K10/12 construct or the individual miRNA miR-K12-1 (B), K12-3 (C) or K12-4-3p (D). Luciferase ratios relative to empty psiCHECK-2 set to 1 are
displayed. (* p,0.01).
doi:10.1371/journal.ppat.1002405.g006
Apoptosis Regulation by KSHV microRNAs
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performed western blot analysis of primary or E6/E7 HUVEC
cells stably transduced with either the EGFP, or the K10/12
lentiviral construct. In four independent experiments, the level of
Casp3 protein was significantly down-regulated in K10/12 cells
compared to the control EGFP cells (average of 0.61-fold,
p = 0.0007) (Figure 7D).
Figure 7. Endogenous Casp3 is regulated by KSHV miRNAs in different cell lines. A. qRT-PCR analysis of Casp3 mRNA expression in non-
infected vs. de novo KSHV-infected HEK293 cells (left panel), and in inducible FLP-pcDNA or FLP-K10/12 cells (right panel), by comparing the non-
treated vs. doxycycline-treated conditions. Error bars represent the standard deviation observed for 3 technical replicates. B. Western blot analysis
and signal quantification from three independent experiments for Casp3 and Tubulin on the inducible FLP-K10/12 cell line, non-doxycycline-treated
vs. doxycycline-treated conditions, and C. DG-75 cells expressing either EGFP or the K10/12 miRNA cluster. D. Western blot analysis and signal
quantification from four independent experiments for Casp3 and Tubulin on primary or E6/E7 HUVEC cells stably expressing either EGFP or the K10/
12 miRNA cluster after lentiviral transduction and antibiotic selection. *indicates experiments done in E6/E7 HUVEC cells. E.Western blot analysis and
signal quantification from three independent experiments for Casp3 and Tubulin on KSHV miRNA inhibited-BC-3 cells. Cells were transfected with a
29-O-methylated oligonucleotide antisense to the control cel-miR-67 (29OMe-miR-67), or with a mix of oligonucleotides antisense to miR-K12-1, K12-3,
and K12-4-3p (29OMe-miR-K12-1/3/4) at the same final concentration, and harvested 48 h later. F. qRT-PCR analysis of Casp3 mRNA expression in
KSHV miRNAs inhibited-BC-3 cells by tiny LNAs treatment. Cells were incubated for 6 days with 8mer LNA-oligonucleotides antisense to the seed
region of the control miR-67 (LNA-miR-67), or with a cocktail of oligonucleotides antisense to miR-K12-1, -3, and 4-3p (LNA-miR-K12-1/3/4) at the
same final concentration. G. Western blot analysis and signal quantification from two independent experiments for Casp3 and Tubulin on the same
cells treated with the indicated tiny LNAs for 48 h (left panel) or 6 days (right panel).
doi:10.1371/journal.ppat.1002405.g007
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In order to assess whether the down-regulation of Casp3 in
naturally KSHV infected cells was caused by the specific presence
of the three previously identified miRNAs, we used an antisense
approach to inhibit specifically miR-K12-1, K12-3 and K12-4-3p.
We thus employed either classical full-length 29-O-methylated
(29OMe) antisense oligoribonucleotides [41], or short Locked
Nucleic Acid oligonucleotides directed only against the seed of
each individual miRNAs (tiny LNAs) [42]. In three independent
experiments, transfection of a cocktail of 29OMe oligonucleotides
against miR-K12-1, K12-3 and K12-4-3p (29OMe-miR-K12-1/
3/4) in BC-3 cells resulted in a modest but measurable increase of
Casp3 protein level compared to a control 29OMe oligonucleotide
(29OMe-miR-67) (1.4-fold on average, p = 0.0486) (Figure 7E).
The advantage of using tiny LNAs to inhibit miRNA function over
the 29OMe oligonucleotides is based on the fact that they do not
require transfection to enter the cells. We therefore tested the
inhibition efficiency of tiny LNAs on luciferase sensors in HEK293
cells and found that they could readily revert the targeted miRNA
regulation (Figure S7). BC-3 cells grown in a medium containing a
cocktail of tiny LNAs each directed against one of the three KSHV
miRNAs listed above (LNA-miR-K12-1/3/4) also showed an 1.8-
fold increase in Casp3 mRNA (Figure 7F) accompanied with a
somewhat milder increase in the protein levels compared to
control tiny LNA (LNA-miR-67) (1.3-fold on average, p= 0.0018)
(Figure 7G; left panel for 48 h, and right panel for 6 days). Taking
these results altogether, we can definitely conclude that Casp3 is
regulated at both mRNA and protein levels by the KSHV-
encoded miR-K12-1, K12-3, and K12-4-3p.
Inhibition of KSHV miRNAs reduce apoptosis in infected
cells
In order to test the biological relevance of the repression of
Casp3 by these KSHV-encoded miRNAs, we decided to look at
Casp3 cleavage or its direct and indirect endogenous cleavage
substrates, such as respectively Poly[ADP-ribose] polymerase-1
(PARP-1) or genomic DNA. We thus treated BC-3 cells with a
cocktail of tiny LNAs directed against the three Casp3-targeting
viral miRNAs, and measured PARP-1 cleavage following
staurosporine treatment for 8 h. In the absence of staurosporine,
inhibition of KSHV miRNAs had no or little effect on PARP-1
levels (Figure S8, left panel). Upon treatment, we found that cells
pre-treated with anti-KSHV specific tiny LNAs (LNA-miR-K12-
1/3/4), but not with the control tiny LNA (LNA-miR-67),
accumulated slightly more of the PARP-1 cleavage product
(Figure S8, right panel). We also tested the effect of this inhibition
using KSHV-infected immortalized lymphatic endothelial cells
(iLECs) by measuring the appearance of cleaved Casp3 and the
extent of apoptosis-induced genomic DNA nicks following a 24 h
etoposide treatment. iLECs represent one of the most relevant cell
types implicated in KSHV pathogenesis [43]. We observed an
increase in the number of cleaved Casp3 positive cells (Figure 8A)
and TdT-mediated dUTP nick end labeling (TUNEL) positive
cells (Figure 8B) over mock-treated (DMSO) controls when miR-
K12-1, K12-3 and K12-4-3p were inhibited with the tiny LNA
cocktail (LNA-miR-K12-1/3/4), over the control. In three
independent experiments, the mean fold induction of etoposide-
induced TUNEL positive cells (over the DMSO treated control)
following inhibition of miRNAs (LNA-miR-K12-1/3/4) was
significantly greater (2.30-fold, p = 0.041) than in cells treated
with the control tiny LNA (Figure 8C). These data suggests that
the KSHV-encoded miR-K12-1, K12-3 and K12-4-3p contribute
to protection of etoposide-induced apoptosis in KSHV infected
iLECs.
Figure 8. KSHV miRNAs inhibit apoptosis in KSHV-infected
endothelial cells. A. Microscopic analysis following DAPI (blue) and
cleaved Casp3 (red) staining of K-iLEC cells treated with DMSO or
etoposide, and after KSHV miRNA inhibition by tiny LNA (LNA-miR-K12-
1/3/4) or the control (LNA-miR-67). Arrows indicate cells that were
counted as cleaved Casp3 positive. Bar size is 10 mM. B. Microscopic
analysis following DAPI (blue) and TUNEL (red) staining of K-iLEC cells
treated with DMSO or etoposide, and after KSHV miRNA inhibition by
tiny LNA (LNA-miR-K12-1/3/4) or the control (LNA-miR-67). Arrows
indicate cells that were counted as TUNEL positive. Bar size is 10 mM. C.
Mean apoptosis fold induction measured from three independent
TUNEL experiments; a significant difference of apoptosis induction
(p = 0.0056) is observed between the LNA-miR-67 and the LNA-miR-K12-
1/3/4 treatment.
doi:10.1371/journal.ppat.1002405.g008
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Discussion
Viral miRNAs have only recently attracted attention in studies
into viral genetics, and their importance during the course of
infection remains to be fully established. Almost all of these
miRNAs were found in viruses belonging to the herpesvirus
family; viruses that are associated with latency and that suggest
long-term disease progression. Like other members of the
gammaherpesvirus subfamily, KSHV is associated with a number
of neoplastic disorders including Kaposi’s sarcoma and B-cell
lymphomas [3]. Some cellular targets of KSHV miRNAs have
been previously reported. For example, miR-K12-11 has been
shown to target a subset of genes that are also targeted by its
homologous human miRNA, miR-155, that shares an identical
seed region with this miRNA [26,27]. Among the validated targets
of miR-K12-11 are two transcription factors, BACH1 and Fos.
Although Fos itself provides a potential link between KSHV
infection and oncogenesis, the authors did not show that KSHV
miRNAs directly participate in cancer progression. The study of
Samols and colleagues identified another potential candidate as a
KSHV miRNA target that could contribute to cell transformation
[39]. Indeed, with a microarray-based approach similar to the one
that was used in this study, they found that thrombospondin
(THBS1), a gene involved in angiogenesis, is regulated by KSHV
miRNA expression. However, the analysis was performed in
HEK293 cells, which are not representing cells naturally infected
by KSHV. More recently, the Ganem laboratory also reported on
the identification of cellular targets of KSHV miRNAs using a
transcriptomic-based approach, with the Bcl2-associated factor
BCLAF1 as one of the identified targets of several KSHV miRNAs
[44]. Other targets of KSHV miRNAs that have been identified
very recently are p21, IkBa, TWEAKR and Gemin 8 [35,45–47].
The aim of this study was to define the role played by KSHV
miRNAs in apoptosis inhibition. The apoptotic processes can be
executed intracellularly by the release of various factors (e.g.
cytochrome c or SMAC/DIABLO) from mitochondria, or
extracellularly through transmembrane death receptors, which
are activated by their ligands. In both the intrinsic and extrinsic
pathways, caspases are recruited and activated, and in turn they
cleave substrates leading to the execution of apoptosis. In the
intrinsic pathway, cytochrome c leaks from mitochondria [48],
and binds to the adaptor apoptotic protease activating factor-1
(APAF1) to form the multi-protein structure, coined the apopto-
some. The latter recruits Casp9, which in turn activates
downstream effector caspases 3, 6 and 7 [49]. In the extrinsic
pathway, ligands such as TRAIL and FasL activate specific pro-
apoptotic death receptors at the cell surface [50–52], which results
in the binding of the intracellular domains of the receptors to the
adaptor protein Fas-associated death domain [53]. This leads to
the assembly of the death-inducing signaling complex DISC, and
to the recruitment of initiator caspases 8 and 10 [54]. Upon
stimulation of these two caspases, effector caspases 3, 6 and 7 are
activated. Thus, the intrinsic and extrinsic pathways converge at
the level of the effector caspases, which highlights Casp3 as a
critical factor in the control of apoptosis. In this study, we observed
that KSHV miRNAs have a negative effect on apoptosis, as
HEK293 cells and DG-75 B lymphocytes expressing these viral
miRNAs are partially protected from apoptosis induction by
staurosporine. We also measured Casp3 activity in the HEK293
cells, and showed that the presence of KSHV miRNAs resulted in
a sharp decrease of Casp3/7 activity upon staurosporine
induction. While our data does not rule out that the observed
effect in HEK293 cells is due to a decreased activity of Casp7, the
evidence available to date indicates that Casp3 activity is
predominant over Casp7 activity, and that Casp3 is likely the
major executor of apoptosis [55]. However, we were unable to
monitor the effect of KSHV miRNA on Casp3/7 activity in DG-
75 cells. Indeed, these cells are resistant to caspase activation by
the intrinsic pathway [36], and accordingly, we could not induce
Casp3/7 cleavage with staurosporine. This result confirms that
Annexin V levels do not only measure caspase-dependent
apoptosis, and therefore indicates that KSHV miRNAs are
regulating both caspase-dependent and -independent apoptosis.
To discover cellular targets of KSHV miRNAs, we used a
microarray-based approach to identify transcripts regulated by
KSHV miRNAs in both the B lymphocyte DG-75 cell line and the
endothelial EA.hy926 cell line. Based on their expression profiles,
the samples primarily clustered according to the cell line (DG-75
or EA.hy926), and, within these two clusters, according to the
presence of KSHV miRNAs. Using small RNA deep-sequencing
data, we determined the relative abundance of each miRNA
within the expressed cluster, which enabled us to show that
transcripts containing seed-matches to KSHV miRNAs within
their 39UTR were significantly more down-regulated that
transcripts without such binding sites. This enabled us to generate
a list of putative targets to follow in further functional assays. Our
validation rate was relatively low, reflecting presumably the fact
that many miRNAs (virus-encoded and endogenous) changed in
these experiments, leading to complex secondary effects. We
looked for seed-match sites within the coding sequences of down-
regulated transcripts and could identify a few (listed in Dataset S1),
but the validation of these sites can prove challenging. Neverthe-
less, we validated two candidate targets that are biologically
relevant for KSHV infection, Rad51AP1 and Casp3. Rad51AP1 is
a DNA binding protein that participates in RAD51-mediated
homologous recombination, and is important for the preservation
of genome integrity [56]. Because KSHV has been shown to
induce DNA damage response through the expression of v-cyclin
[57], the down-regulation of Rad51AP1, which will require further
validation, might be important in the context of viral infection. In
light of our initial aim to define the role of KSHV miRNAs in
apoptosis inhibition, we focused our efforts on the characterization
of Casp3 as a target of KSHV miRNAs. We confirmed that a
Casp3 39 UTR luciferase reporter construct is regulated by three
KSHV miRNAs, and we identified three miRNAs, miR-K12-1,
miR-K12-3 and miR-K12-4-3p, as being responsible for this
regulation, as well as their binding sites within Casp3 39 UTR.
We then showed that endogenous Casp3 was also regulated by
KSHV miRNAs, both at the mRNA and protein levels, and in
different cell types. We also showed that inhibition of miR-K12-1,
K12-3 and K12-4-3p in KSHV-infected cells resulted in an
upregulation of Casp3 expression, which in turn translated into an
increase in apoptosis, as assessed by cleaved Casp3 quantification
and TUNEL assay analysis. These findings are consistent with a
report that described the role of KSHV in conferring a survival
advantage to endothelial cells [58]. In this report, Wang et al.
showed that the level of Casp3 activity was decreased in KSHV-
infected HUVEC cells subjected to staurosporine treatment (or
other apoptotic insults). The regulation of Casp3 is not the only
explanation for KSHV miRNAs-mediated inhibition of apoptosis,
especially since we showed that caspase-independent apoptosis was
also affected. It is of course highly probable that other factors in
the apoptosis pathway are also targeted by KSHV miRNAs. For
example, Abend et al. recently reported that KSHV miR-K12-10
targeted the TNF-like weak inducer of apoptosis (TWEAK)
receptor [47], which indicates another level of regulation of one
certain type of apoptosis.
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In summary, our findings demonstrate that KSHV miR-K12-1,
K12-3 and K12-4-3p target the effector caspase 3. The down-
regulation of Casp3 by KSHV miRNAs results in a decrease in
apoptosis activity in different cell types including endothelial cells
that are biologically relevant for KSHV infection in vivo. The
specific inhibition of these miRNAs in infected cells increased
Casp3 levels and cell death. Apoptosis is frequently inhibited in
tumor cells, and our results are in agreement with a recent report
that indicates that the active form of Casp3 is detected less
frequently in Kaposi sarcoma lesions in patients from Brazil [59].
Our data therefore suggests that apoptosis regulation by the viral
miRNAs could contribute to the malignant phenotype triggered by
KSHV infection. In the long term, delivery of specific inhibitors of
these viral miRNAs in KSHV-infected patients to restore
apoptotic clearance of the virus by the immune system could be
an interesting novel therapeutic approach.
Material and Methods
Cell lines
DG-75 and BCBL-1 cells (obtained through the NIH AIDS
Research and Reference Reagent Program (Cat# 3233 from
McGrath and Ganem)) were grown in RPMI 1640 medium
containing 10% fetal calf serum (FCS), 100 UI/mL penicillin,
100 mg/mL streptomycin and 2 mM L-Glutamine. BC-3 cells
(ATCC) were grown in the same media with 50 mM ß-
Mercaptoethanol. EA.hy926, QBI-HEK 293A (QBiogene), Flp-
In T-REx-293 (Invitrogen), and HEK293 cell lines were grown in
DMEM supplemented with 10% FCS and penicillin/streptomy-
cin. Primary and E6/E7 HUVEC cells (from Promocell) were
cultured in a humidified 5% CO2 atmosphere at 37uC in
endothelial basal medium (Promocell) supplemented with 10%
FCS, gentamicin, amphotericin and supplement kit provided with
the media. To obtain immortal lymphatic endothelial cells (iLECs)
primary human LEC cells (Promocell) were immortalized by the
HPV oncogenes E6/E7 as previously described (Moses et al.,
1999). iLEC cells were maintained in endothelial basal medium
(Promocell) supplemented with 5% human AB serum (HS; Sigma,
St. Louis, Mo.).
KSHV infection of iLECs
Wildtype KSHV was produced from BCBL-1 cells induced with
20 ng/mL PMA. The virus-containing supernatant was collected
after three days by ultracentrifugation (21,000 rpm at 4uC for 2 h),
and resuspended in TNE buffer (150 mM NaCl, 10 mM Tris
pH 8, 2 mM EDTA, pH 8). For the KSHV infection iLEC cells
were plated in 6-well plates one day before the infection using
multiplicity of infection (MOI) 1 in the presence of 8 mg/mL
polybrene (Sigma). The infection was performed as spin-infection
by centrifugation at 2500 rpm (Heraeus Multifuge 3 S-R; Thermo
Scientific) for 30 min at room temperature. Cells were then
returned to 37uC, 5% CO2, and after 4 h of incubation fresh
complete media was added. The virus-containing medium was
removed the next day, and replaced with fresh complete media.
The extent of KSHV infection was monitored by expression of the
latent nuclear antigen-1 LANA-1 in the nuclei of KSHV-infected
cells (K-iLECs) and detected by immunofluorescence using anti-
LANA antibody (13-210-100, Advanced Biotechnologies Inc).
Primary rKSHV infection of HEK293 cells
rKSHV.219 infected HEK293 cells were reactivated by
incubating them in DMEM medium containing 1 mM sodium
butyrate and 20 ng/mL TPA (tetradecanoyl phorbol acetate) for
24 h, and four more days with media containing sodium
butyrate only. The supernatant was collected, filtrated through
0.45 mM filter, and 8 mg/mL polybrene was added before
adding the supernatant to QBI-HEK 293A cells seeded one
day before. After 4 h, the medium was replaced and the cells
grown at 37uC for 2 days. As soon as green fluorescent started to
appear, 1 mg/mL puromycin was added to the medium. Cells
were harvested for RNA analysis after at least 21 days under
puromycin selection.
Generation of stable cell lines expressing KSHV miRNAs
Cell lines stably expressing the ten intronic KSHV miRNAs
were generated using the ‘‘Virapower’’ lentiviral transduction
system with the vector pLENTI6/V5 (Invitrogen) and Gateway
cloning. The miRNA encoding intronic region was amplified by a
two-step PCR using cDNA prepared from KSHV infected BCBL-
1 cells (PCR primers: KSHV miRK_for and KSHV miRK_rev
for the first PCR and attB1_external for and attB2_external rev for
the second PCR), cloned into pDONR207 and transferred to
pLENTI6/V5-DEST (Invitrogen). PCR primers are provided in
Table S3. The control lentiviral vector pLENTI6/V5-EGFP was a
kind gift from Oliver Rossmann. In order to generate lentiviruses
for transduction of cells with KSHV miRNAs, the ViraPower
Lentiviral Gateway Expression System (Invitrogen) was employed
according to the manufacturer’s instructions. The packaging mix
contained plasmids pLP1, pLP2 and pLP/VSVG. Virus-contain-
ing medium was cleared with a 0.45 mm filter and added with
polybrene (8 mg/mL) to DG-75 (16106 cells/mL) or EA.hy926
(36105 cells/mL) target cells for transduction. In the case of
EA.hy926 cells, the plates were centrifugated 30 min at 2500 rpm
to increase transduction efficiency. Two days after transduction,
when the EGFP signal in the control cells became visible,
Blasticidin (1 mg/mL) was added to the medium to select for the
transgene and gradually raised to a final concentration of 7.5 mg/
mL for DG-75 cells and 3 mg/mL for EA.hy926 cells after six
days. Efficiency of selection was determined by analyzing the
proportion of EGFP expressing control cells by fluorescence
activated cell sorting (FACS). Cell lines were used for experiments
when 100% of control cells expressed EGFP.
Primary HUVEC cells were transduced with lentiviruses
(pLenti6-vector; Invitrogen) encoding EGFP or 10/12 KSHV
miRNA cluster (K10/12) and maintained under blasticidin
selection (5 mg/mL) in endothelial basal medium supplemented
as above. The cells were replenished with fresh medium every
second day and passaged when necessary.
Generation of inducible FLP-293 stable cell lines
The Flip-In stable cell lines were generated using the Flp-In T-
REx-293 cell line (Invitrogen) and according to the manufacturer’s
instructions (Invitrogen). Briefly, cells were seeded one day before
at 106 cells/well in 6-well plates. Cells were transfected with
3.6 mg and 0.4 mg respectively of pOG44 (Invitrogen) and each
pcDNA for each cell line with lipofectamine 2000 (Invitrogen).
The media was replaced 24 h after transfection, and cells were
passaged into 10 cm dishes 24 h later to achieve a desired
confluency of maximum 25% prior selection. Hygromycin
(Invivogen) was added at a concentration of 200 mg/mL and then
raised 2–3 days later at a concentration of 250 mg/mL. The media
was replaced each 3–4 days until 2–3 mm wide foci appeared.
Cells were then passaged into 75 cm2 flasks for amplification.
Efficiency of the selection was then assayed by b-galactosidase
staining, for the loss of b-galactosidase activity, and/or by
northern blot for the detection of the miRNA.
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Computational microarray analysis
The microarray data were submitted to the gene expression
omnibus database (http://www.ncbi.nlm.nih.gov/geo) under the
accession number GSE18946. We imported the CEL files into the
R software (R Development Core Team (2008). R: A language
and environment for statistical computing. R Foundation for
Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0,
http://www.R-project.org) using the BioConductor affy package
[57]. The probe intensities were corrected for optical noise,
adjusted for non-specific binding and quantile normalized with the
gcRMA algorithm [58].
Per gene log2 fold change was obtained through the following
procedure. We first fitted a lowess model of the probe log2 fold
change using the probe AU content. We used this model to correct
for the technical bias of AU content on probe-level log2 fold
change reported by [59]. Subsequently, probe set-level log2 fold
changes were defined as the median probe-level log2 fold change.
Probe sets with more than half of the probes (6) mapping
ambiguously (more than 1 locus) to the genome were discarded, as
were probe-sets that mapped to multiple genes. We then collected
all remaining probe sets matching a given gene, and averaged their
log2 fold changes to obtain an expression change per gene. For
sequence analyses, we selected for each gene the RefSeq transcript
with median 39 UTR length corresponding to that gene.
Controls and transductions were performed in triplicates in both
cell lines (DG-75, EA.hy926), and we used limma [60] to compute
differential regulation p-values. Finally, for each cell line, we only
analyzed genes which had at least one probe set that was called
present in either all replicates of miRNA transduction or all
replicates of the control (or both).
Transcriptome-wide regulatory effect of the KSHV
miRNAs. To determine whether transduction of the KSHV
miRNAs had the expected effect on mRNA expression, we first
computed a KSHV miRNA sensitivity score for each mRNA. This
was defined as the sum over all KSHV miRNAs, the number of
seed matches to the KSHV miRNA in the 39 UTR weighted by
the relative abundance of the KSHV miRNA. The KSHV
miRNA expression was determined in DG-75 cells by Illumina
small RNA sequencing and the relative abundance of a miRNA
was defined as the number of reads that mapped to this KSHV
miRNA divided by the total number of reads that mapped to any
KSHV miRNA. Because the relative abundance of KSHV
miRNAs was comparable in DG-75 and EA.hy926 cells (Table
S1 and Figure S4), we used the same KSHV miRNA sensitivity
score to analyze the DG-75 and the EA.hy926 microarrays. The
Human Genome U133 Plus 2.0 Affymetrix microarrays used in
this study measure the expression of a total of 15678 genes. Of
those, we selected the 1000 genes with the highest KSHV miRNA
sensitivity score as the most likely targets of KSHV miRNAs. Of
those, 611 genes were actually expressed in DG-75 cells and 674 in
EA.hy926 cells. We compared the fold change of these genes with
those that had no KSHV miRNA seed match in their 39 UTR
(2047 expressed genes in DG-75 and 2137 expressed genes in
EA.hy926) using a two-sided Wilcoxon rank sum test. The bar
plots in Figure 3A represent the mean and two standard errors
around the mean fold change of KSHV sensitive mRNAs and
mRNAs with no seed matches in their 39 UTR.
To test whether the 39 UTR length could alone explain the
downregulation of the KSHV sensitive mRNAs in cells transduced
with KSHV miRNAs, we sampled 1000 genes in such way that
their 39 UTR length distribution was identical to that of the
KSHV sensitive mRNAs. For each cell line, we then computed the
average fold change of the subset of these 1000 genes that were
actually expressed. Finally, we repeated this procedure 1000 times.
The mean fold change and two standard errors around the mean
over these 1000 randomizations are reported on Figure 3A (blue
bars).
List of putative direct targets. Transcripts that are direct
targets of the intronic KSHV miRNAs would ideally carry at least
one seed match to at least one of the intronic KSHV miRNA, and
it should be down-regulated in the KSHV miRNAs transduction
compared to the EGFP control transduction.
We considered that an mRNA was down-regulated if its log2
fold change was negative and the limma p-value of differential
regulation smaller than 0.05. In addition, we only considered
genes for which the magnitude of down-regulation was between
40% and 300% (log2 fold M: 22,M,20.5). Through applying
these criteria, we generated three lists of putative direct targets:
one for the DG-75 cells, one for the EA.hy926 cells, and then
intersected these two lists to generate a list of putative direct targets
that are common to DG-75 and EA.hy926.
Generation of inducible miRNA expression and luciferase
sensor vectors
To generate the pcDNA-K10/12, the KSHV intronic miRNA
cluster was PCR-amplified from BAC36 DNA [60] and ligated
into the Bam HI and Xho I sites of the pcDNA5/FRT/TO
(Invitrogen). The primer sequences were (sense and antisense
primers are indicated in respective order): 59-ATATGGATCC-
GAATGCGTGCTTCTGTTTGA, 59-ATATCTCGAGTTTA-
CCGAAACCACCCAGAG. The empty pcDNA vector was
obtained by digesting the pcDNA-K10/12 with Pme I, followed
by ligation of the plasmid. For KSHV miRNA individual
expression vectors, a region of approximately 300 nt surrounding
each pre-miRNA (or the miRNA cluster) was PCR-amplified from
BAC36 DNA. attB1/2 sequences were added by nested PCR and
the resulting PCR product were cloned into pDONR207
(Invitrogen) and then recombined in pLenti6/V5-DEST using
Gateway technology (Invitrogen). The attB1/2 primer sequences
are (sense and antisense primers are indicated in respective order):
59-ACAAGTTTGTACAAAAAAGCAGGCT, 59-ACCACTTT-
GTACAAGAAAGCTGGGT. The specific primers are indicated
in Table S3. The individual miRNA expression cassettes were
then subcloned via PCR amplification from pLenti6/V5-DEST
expressing vectors and ligated into the Xho I and Apa I sites of
pcDNA5/FRT/TO, and with the primers indicated in Table S3.
To generate luciferase reporter plasmids, psiCHECK-2 (Promega)
was modified by inserting the Gateway cassette C.1 (Invitrogen) at
the 39-end of the firefly luciferase gene into the Xba I site of
psiCHECK-2. attB-PCR products were cloned into pDONR/Zeo
(Invitrogen) and recombined in the modified psiCHECK-2 vector
by Gateway cloning. The 39 UTR sequence of the different
candidates were obtained from the Ensembl database (www.
ensembl.org) and were nested PCR-amplified from QBI-HEK
293A cells’ genomic DNA with the primers indicated in Table S3
and attB1/2 primers. The imperfect match sensors for KSHV
miRNA were obtained by annealing the oligonucleotides indicated
in Table S3 and PCR-based addition of the attB sequences using
attB1/2 primers. The resulting PCR product was then cloned by
Gateway recombination sequentially in pDONR/Zeo and psi-
CHECK-2 plasmids.
Mutagenesis of Casp3 luciferase sensor
Mutagenesis was performed using QuikChange Lightning Site-
Directed Mutagenesis Kit (Agilent Technologies) according to the
manufacturer’s instructions and using the oligonucleotides indi-
cated in Table S3. Briefly, we mutagenised in the Casp3 luciferase
reporter construct the nucleotides predicted to pair to position 3 to
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5 of the miRNA sequence to prevent pairing of the miRNA seed
sequence on Casp39s predicted target sites.
Luciferase assays
QBI-HEK 293A cells were seeded in 48-well plates at 105 cells/
well and then incubated a few hours. When cells were adherent,
co-transfection of 25 ng of the reporter constructs and 250 ng of
the pcDNA-K10/12 (or pcDNA as control vector) were performed
using Lipofectamine 2000 (Invitrogen). After 48 h, cells were then
washed in PBS and lysed with 65 mL of passive lysis buffer
(Promega), and 10 mL were assayed for firefly and Renilla luciferase
activity, using the dual-luciferase reporter assay system (Promega)
and a luminescence module (Glomax, Promega). The relative
reporter activity was obtained by first normalizing to the
transfection efficiency with the Renilla activity, and then, to the
firefly activity obtained for the empty control reporter, in presence
of the pcDNA-K10/12 or pcDNA, to normalize for the effect of
transfection of these expression vectors.
Western blot analysis
For Western blot analysis of HUVEC cells, cells were extracted
in ELB lysis buffer (150 mM NaCl; 50 mM HEPES, pH 7.4;
5 mM EDTA and 0.1% NP40) and 30 mg of proteins was
separated on 12% SDS-PAGE and transferred on to nitrocellulose
membranes according to standard protocols. Primary antibodies
used in Western blotting were anti-caspase-3 (MAB4603; Milli-
pore) and anti-c-tubulin (GTU-88; Sigma-Aldrich). HRP-conju-
gated anti-mouse (AP308P; Chemicon) immunoglobulin was used
as a secondary antibody. Filters were visualized on SuperRX film
(Fuji) using the ECL chemiluminescence system (Pierce, Rockford,
IL). The intensity of the chemiluminescence signals was quantified
with FluoChem 880 imager and software (Alpha Innotech
Corporation).
For Western blot analysis of DG-75, BC-3 or FLP-293 cells,
cells were extracted in passive lysis buffer (50 mM Tris, 150 mM,
NaCl, 5 mM EDTA and 0.5% NP40, 10% Glycerol and 10 mM
MG132) and 15 mg or 45 mg of proteins, respectively from BC-3
or FLP-293 cells, was separated on 10% SDS-PAGE for PARP
analysis, or on 15% SDS-PAGE for Casp3 analysis, and
transferred on to nitrocellulose membranes according to standard
protocols. Primary antibodies used in Western blotting were anti-
caspase-3 (06-735; UpState), anti-PARP-1 [61] and anti-c-tubulin
(GTU-88; Sigma-Aldrich). IRDye 800CW-conjugated anti-rabbit
and anti-mouse (926-32213 and 926-32212; Li-Cor Biosciences)
immunoglobulins were used as secondary antibodies. The intensity
of the fluorescence signals was quantified with Odyssey Infrared
Imaging system and Odyssey v3.0 software (Li-Cor Biosciences).
Northern blot analysis
RNA was extracted using Trizol reagent (Invitrogen) and
Northern blotting was performed on 5 to 10 mg of total RNA as
described before [23,62]. Probes were 59 32P-radiolabelled
oligodeoxynucleotides antisense to the miRNA sequence or to
part of the U6 snRNA sequence. Blots were analyzed and
quantified by phosphorimaging using a FLA5100 scanner (Fuji).
Small RNA cloning and sequencing
Small RNA cloning was conducted from 50 mg of DG-75-K10/
12 total RNA as previously described [63]. Small RNA sequencing
was performed at the Institut de Ge´ne´tique et de Biologie
Mole´culaire et Cellulaire (IGBMC, Illkirch, France) using an
Illumina Genome Analyzer II with a read length of 36 base pairs
(bp).
Processing and annotation of small RNA sequences
An in-house Perl analysis pipeline was used to analyze the data
produced by small RNA sequencing. After 39 adaptor removal and
size selection (exclusion of trimmed reads shorter than 15 nt), non-
redundant sequences were mapped to the genomes from which
they may derive and to other RNAs already annotated, using
Nexalign (http://genome.gsc.riken.jp/osc/english/software/src/
nexalign-1.3.5.tgz) permitting up to 2 mismatches. The Homo
sapiens and KSHV genome sequences were respectively down-
loaded from the UCSC repository (assembly version hg19) and the
GenBank database. The following sources of annotated transcripts
were used: miRBase v.16 for miRNAs, GenBank v.180 for Homo
sapiens rRNA, tRNA, sn-snoRNA, scRNA and piRNA, and
Repbase v.16.01 for Homo sapiens and common ancestral repeats.
By doing so, small RNAs that mapped unambiguously to
sequences from one single functional category were easily
classified, while the other ones were identified by applying this
annotation rule based on the abundance of various types of
sequences in the cell: rRNA . tRNA . sn-snoRNA . miRNA .
piRNA . repeat . pathogen genome . host genome .
unknown.
cDNA synthesis and quantitative real-time PCR
miRNAs. Semi-quantitative real-time PCR for KSHV
miRNAs was performed using the Light Cycler System (Roche)
with a modified protocol from Shi and Chiang [64]. Briefly, total
RNA was extracted with Trizol (Invitrogen) and provided with a
39 poly-A-tail (Poly-A-Tailing Kit, Ambion). After phenol-
chloroform extraction and ethanol-acetate precipitation, first
strand synthesis with the anchor primer Poly(t)adpt was
performed using Superscript II reverse transcriptase (Invitrogen).
Quantification of miRNAs was performed using the FastStart
DNA MasterPlus SYBR Green I Master Mix (Roche) with specific
primer and AdptRev-primer. The PCR program was composed of
an initial activation step for the Taq polymerase at 95uC for
10 min followed by 45 cycles of 95uC for 10 sec, 68uC for 5 sec
(DT=20uC/sec each) and 72uC for 6 sec (DT=5uC/sec). 5.8S
RNA was quantified and the results used for normalization. The
changed levels of miRNA transcripts (relative to 100%) were
calculated based on the empiric formula ‘‘level(%) = 1,8‘DCt’’,
based on quantification of synthetic miRNAs (data not shown).
Primers used are shown in Table S3.
Caspase 3. To monitor the expression of Casp3 mRNA
levels, cDNA was prepared from total RNA using Superscript II
(Invitrogen). Transcripts were quantified by TaqMan PCR using
the ABI Prism 7000 sequence detection system (Applied
Biosystems). TaqMan probes were taken from the Universal
Probe Library (Roche) and selection of probe-primer
combinations was performed using the Assay Design Centre
(Roche, www.universalprobelibrary.com). The PCR program was
composed of a denaturation step at 94 uC for 12 min followed by
45 cycles of 95uC for 20 sec and 60uC for 1 min 72uC for 6 sec
(DT=5ufC/sec). HPRT-transcript was used for normalization of
Ct-values. The changed levels of Casp3 transcripts (relative to
100%) were calculated based on the empiric formula
‘‘level(%) = 2‘DCt’’.
The primers used were: RT_CASP3_for, RT_CASP3_rev and
Roche universal probe#68; RT_HPRT_for, RT_HPRT_rev and
Roche universal Probe #73 (sequences can be found in Table S3).
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BC-3 cells miRNAs inhibition with 29O-methylated or LNA
oligonucleotides
For inhibition of miRNAs, BC-3 cells were cultured in 6-well
dishes and transfected with the 29O-methylated oligonucleotides
(provided by G. Meister) against individual KSHV miRNAs using
Oligofectamine (Invitrogen). Oligonucleotides were used at a final
concentration of 60 nM and transfections were performed
according to manufacturer’s instructions. Total proteins were
extracted for analysis 48 h after transfection.
For inhibition of miRNAs with tiny LNAs, 26106 BC-3 cells
were seeded in 6-well plates and incubated with the inhibitors
(Table S3) against individual KSHV miRNAs or the control C.
elegans miR-67. Oligonucleotides were used at a final concentration
of 1.5 mM and incubated in the medium for 48 h, or 6 days by
replacing twice the medium (day 2 and 5), prior to harvesting the
cells.
Annexin V and Casp3/7 activity cell death assays
The effects of the KSHV miRNAs on apoptosis were analysed
by both measurement of caspase 3/7 activity and Annexin V/
propidium idiode (PI) staining. Cell death was induced by adding 2
to 5 mM staurosporine (Sigma) for 8 h; DMSO was used as a
control. For Annexin V binding analysis, 105 HEK293 cells were
seeded in 12-well plates, incubated overnight prior to addition of
staurosporine or DMSO. Cells were harvested by trypsinization,
washed in PBS, and resuspended in binding buffer (10 mM
Hepes/NaOH (pH 7.4), 140 mM NaCl, 2.5 mM CaCl2) contain-
ing Annexin V conjugated with Allophycocyanin diluted at 1/100
(BD Biosciences, Le Pont-de-Claix France) and 2 mg/mL PI
(Sigma-Aldrich, Lyon, France). The cells were incubated for
15 min in the dark and analyzed with a FacsCalibur flow
cytometer (Becton Dickinson, Le Pont-de-Claix, France).
Statistical analysis for Annexin V geo means collected in
individual experiments were performed using a Wilcoxon signed-
paired rank test, as distribution of measurements in each condition
did not fit normality tests. Differences were considered significant
when p,0.05.
For caspase 3/7 activity assay, 2.56104 cells were seeded in 96-
well plates, and staurosporine or DMSO immediately added.
Caspase 3/7 activity was then measured using Caspase-Glo 3/7
Assay Kit (Promega) and normalized to the protein concentration
determined by DC Protein Assay (Bio-Rad).
Cleaved Casp3 quantification and TUNEL assay
KSHV infected immortalized (by stable expression of HPV16
E6/E7) human Lymphatic Endothelial Cells (K-iLEC) were
seeded one day before at 56104 cells/well on 24-well plates. For
inhibition of miRNAs, K-iLEC cells were treated with two doses of
Tiny LNA oligonucleotides (48 h+48 h) at a final concentration of
1,5 mM. Apoptosis was induced with 500 mM Etoposide (Sigma
Aldrich) and DMSO was used as a vehicle control (mock). Cells
were fixed with 4% Paraformaldehyde (EMS, Hatfield, PA) 24 h
after the treatment with Etoposide or mock. Coverslips were
blocked 30 minutes with 5% goat serum and incubated first with
1:800 diluted Cleaved Caspase-3 (Asp175) rabbit monoclonal
antibody (Cell signaling) for 1 h at room temperature, then with a
1:1000 dilution of a goat anti-rabbit secondary antibody coupled
to Alexa Fluor 594 (Invitrogen). Alternatively, apoptosis was
detected with TdT-mediated dUTP nick end labeling (TUNEL)
assay according to manufacturer’s instructions of the kit (In situ
Cell Death Detection Kit, TMR red, Roche, Mannheim,
Germany). The fluorochromes were visualized with a Zeiss
Axioplan 2 fluorescent microscope (Carl Zeiss, Oberkochen,
Germany). Images were acquired with a Zeiss Axiocam HRc,
using Zeiss AxioVision (version 4.5 SP1) and Adobe Photoshop
software (version 7.0; Adobe, San Jose, CA).
Supporting Information
Dataset S1 Microarray analysis summary. Each row in the table
represents one of the 15768 genes monitored by the Affymetrix
arrays. The ‘‘RefSeq mRNA’’, ‘‘Gene Name’’, ‘‘Entrez Gene ID’’,
‘‘gene description’’ and ‘‘mRNA annotation’’ columns contain the
same information as in Dataset S2, S3 and S4 (see below). The
‘‘KSHV sensitivity 39 UTR’’ and ‘‘KSHV sensitivity CDS’’
columns contain the KSHV miRNA sensitivity score described in the
methods for the 39 UTR and the Coding Region, respectively.
The ‘‘mRNA presence DG-75’’ and ‘‘mRNA presence EA.hy926’’
columns indicate whether the gene was called present by the
Affymetrix arrays in each cell line. The ‘‘39 UTR hits’’ and ‘‘CDS
hits’’ then indicate how many matches to the KSHV miRNAs
were found in the 39 UTR and in the Coding Region. The
remaining fields (log2 mRNA fold change, log2 intensity,
differential expr. P-value) are defined as in Dataset S2, S3 and
S4 (see below).
(XLS)
Dataset S2 Putative direct targets of the KSHV miRNAs in
DG75 cells. Each row in the table corresponds to one gene,
identified by a representative RefSeq mRNA ID, a set of
Affymetrix probes designed to monitor the expression of that
gene, the Entrez Gene ID, the gene name and the gene description
provided by NCBI RefSeq. The ‘‘mRNA annotation’’ field
provides information about the length and the span of the Coding
Domain of the representative mRNA used for the analysis. ‘‘log2
fold change K10/12 vs EGFP’’ contains the log2 fold changes in
gene expression upon transducing the K12/10 construct com-
pared to the EGFP control, while ‘‘log2 intensity’’ is the average
signal intensity on the microarrays. ‘‘diff. Expression p-value’’ is
the (uncorrected) P-value of differential expression as computed by
the limma algorithm. The ‘‘Detectable’’ field is true whenever the
gene could be detected in at least one of the samples from the
corresponding cell line. Finally, the two ‘‘Seed matches to K10/12
miRNAs’’ field indicates the KSHV miRNAs for which at least
one match to the seed recognition motif could be found in the 39
UTR of the representative RefSeq mRNA. The procedures we
used to build this table are described in the ‘‘Methods’’ section.
(XLS)
Dataset S3 Putative direct targets of the KSHV miRNAs in
EA.hy926 cells. For details, please refer to Dataset S2 legend.
(XLS)
Dataset S4 Putative direct targets of the KSHV miRNAs in
both cell lines. For details, please refer to Dataset S2 legend.
(XLS)
Figure S1 Northern blot analysis of BCBL-1, BC-3 and FLP-
pcDNA and FLP-K10/12 cells grown in doxycycline-containing
medium (final concentration of 1 mg/ml). U6 was used as a
loading control.
(TIF)
Figure S2 The relative abundance of KSHV miRNAs is similar
in K10/12 transduced DG-75 cells and K10/12 EA.hy926 cells.
Each dot on the scatter represents one KSHV miRNA whose
expression in KSHV-infected BCBL1 cells, DG-75 cells and
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EA.hy926 was quantified by qPCR. Plotted are the expression
levels of these KSHV miRNAs in DG-75 cells (x-axis) and
EA.hy926 relative to their BCBL1 levels.
(TIF)
Figure S3 Clustering of gene expression profiles follows first the
cell line (DG-75 vs. EA.hy926), and within each cell line the
treatment (transduction of KSHV miRNAs vs EGFP). Shown is
the hierarchical clustering of all microarray samples on the
Euclidean space of log2 expression levels with Ward linkage, and
using all 15,678 genes monitored by the microarrays.
(TIF)
Figure S4 Correlation between changes in gene expression upon
transducing the K10/12 vs EGFP constructs in DG-75 vs
EA.hy926 cells for all 6916 genes whose expression is detectable
in both cell lines.
(TIF)
Figure S5 mRNAs likely to be targeted by KSHV miRNAs are
longer than mRNAs with no matches to KSHV miRNAs. The red
and green histograms respectively represent the distribution of 39
UTR length of the 1000 mRNAs with highest KSHV miRNA
sensitivity score (see methods) and all mRNAs with no matches to
KSHV miRNAs.
(TIF)
Figure S6 Caspase 39UTR fragments are all potentially targeted
by KSHV miRNAs. A. Schematic representation of Casp3 39
UTR luciferase reporter and fragments. The seed-match types are
described in the text. Either the full length 39 UTR, or fragments
spanning the UTR were cloned downstream of the firefly
luciferase in the pSi-Check2 vector. B. Dual luciferase assays
performed with the constructs depicted in A, no fragment of Casp3
UTR showed a stronger repression than the full-length UTR.
(TIF)
Figure S7 Tiny LNAs inhibition effect on KSHV miRNAs and
Casp3 luciferase sensors. Dual luciferase assays performed with the
indicated sensors co-transfected with the empty pcDNA or pcDNA
expressing the K10/12 construct, and incubated with a mix of
either control cel-miR-67, or with a mix of oligos antisense to miR-
K12-1, -3, and 4-3p, at a final concentration of 1,5 mM. Luciferase
ratios relative to empty psiCHECK-2 set to 1 are displayed.
(TIF)
Figure S8 Western blot analysis and signal quantification for
PARP-1 and Tubulin on BC-3 cells treated with DMSO (left) or
0.5 mM Staurosporine for 8 h (right), and tiny LNA-oligonucleo-
tides for control miR-67 (LNA-miR-67), or with a cocktail of
oligonucleotides antisense to the seed region of miR-K12-1, K12-
3, and K12-4-3p (LNA-miR-K12-1/3/4). Arrows and arrowheads
indicate the signals corresponding to PARP-1, and cleaved PARP-
1 respectively; the asterisk indicates a non-specific band. Though
the juxtaposed lanes are not contiguous, all of them are from a
single gel (indicated by the dotted line).
(TIF)
Table S1 Repartition of KSHV miRNAs in DG-75-K10/12
cells as assessed by small RNA cloning and Solexa-based
sequencing.
(DOC)
Table S2 RT-PCR analysis of KSHV miRNAs expression in
DG75 and EA.hy926 cell lines compared to BCBL1. n.d., not
determined; mol., molecules
(DOC)
Table S3 Sequences of primers used in this study. Sequences of
primers for luciferase miRNA sensors (A), target validation (B) and
(C), miRNA expression in pcDNA (D), viral miRNAs qRT-PCR
(E), cellular mRNAs qRT-PCR (F), tiny LNAs (G) and for
mutagenesis of miRNA binding sites in Casp3 39UTR (H) are all
given 59 to 39.
(XLS)
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